Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MCHR1 | Q99705 | 7/20 | 0.37 |
| ▸ | NMT2 | O60551 | 6/20 | 0.35 |
| ▸ | NMT1 | P30419 | 6/20 | 0.35 |
| ▸ | HPGDS | O60760 | 1/20 | 0.33 |
| ▸ | GPR132 | Q9UNW8 | 2/20 | 0.33 |
| ▸ | ADAM17 | P78536 | 1/20 | 0.32 |
| ▸ | MMP12 | P39900 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30714649 | 0.91 | GPR132 (0.42) | GPR132 | |
| SCHEMBL26869173 | 0.84 | BRD4 (0.38) | — | |
| SCHEMBL30714702 | 0.84 | HPGD (0.33) | MCHR1NMT1HPGDSADAM17MMP12 | |
| SCHEMBL30714560 | 0.83 | PARP15 (0.39) | HPGDS | |
| SCHEMBL30714755 | 0.83 | PARP15 (0.41) | MCHR1ADAM17 | |
| SCHEMBL30714631 | 0.82 | OPRL1 (0.33) | MCHR1ADAM17MMP12 | |
| SCHEMBL30714668 | 0.82 | PARP15 (0.40) | HPGDS | |
| SCHEMBL30714652 | 0.81 | ADAM17 (0.34) | ADAM17MMP12 | |
| SCHEMBL24484931 | 0.80 | SLC26A4 (0.44) | — | |
| SCHEMBL29629692 | 0.80 | SLC26A4 (0.44) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250376461-A1 | INDAZOLE DERIVATIVES FOR TREATING TRPM3-MEDIATED DISORDERS | UNIV LEUVEN KATH (BE) | 2025-12-11 | — | — | US | disclosed |
| CN-119968362-A | Indazole derivatives for the treatment of TRPM3 mediated disorders | 勒芬天主教大学 | 2025-05-09 | — | — | CN | disclosed |
| EP-4499624-A2 | INDAZOLE DERIVATIVES FOR TREATING TRPM3-MEDIATED DISORDERS | Katholieke Universiteit Leuven KU Leuven Research & Development (BE) | 2025-02-05 | — | — | EP | disclosed |
| WO-2023230540-A2 | INDAZOLE DERIVATIVES FOR TREATING TRPM3-MEDIATED DISORDERS | KATHOLIEKE UNIVERSITEIT LEUVEN (BE) | 2023-11-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250376461-A1 | INDAZOLE DERIVATIVES FOR TREATING TRPM3-MEDIATED DISORDERS | TRPV3, TRPM2, TRPV1 | MCHR1 1891/4885NMT2 680/4885NMT1 700/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.